Immunocore Holdings plc
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
IMCR$32.38+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
| Incorporation by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | Schedule/Form | FileNumber | Exhibit | Filing Date |
| 3.1 | Articles of Association of Immunocore Holdings plc | 10-Q | 001-39992 | 3.1 | August 8, 2024 |
| 4.1 | Deposit Agreement | 20-F | 001-39992 | 2.2 | March 25, 2021 |
| 4.2 | Form of American Depositary Receipt (included in Exhibit 4.1) | 20-F | 001-39992 | 2.3 | March 25, 2021 |
| 4.3 | Description of Registered Securities | 20-F | 001-39992 | 2.4 | March 25, 2021 |
| 4.4 | Indenture, dated as of February 2, 2024, by and between the Company and U.S. Bank Trust Company, National Association, as Trustee. | 8-K | 001-39992 | 4.1 | February 2, 2024 |
| 4.5 | Form of Global Note, representing the Company’s 2.50% Convertible Senior Notes due 2030 (included as Exhibit A to the Indenture filed as Exhibit 4.1). | 8-K | 001-39992 | 4.2 | February 2, 2024 |
| 4.6 | First Supplemental Indenture, dated as of March 17, 2025, by and between the Company and U.S. Bank Trust Company, National Association, as Trustee. | 8-K | 001-39992 | 4.1 | March 17, 2025 |
| 10.1 | Subscription Agreement between the Registrant and the Bill & Melinda Gates Foundation, dated February 3, 2021 | F-1/A | 333-252166 | 4.3 | February 3, 2021 |
| 10.2 | Amended and Restated Global Access Commitments Agreement, dated as of March 2, 2020, between the Registrant and the Bill & Melinda Gates Foundation | F-1 | 333-252166 | 10.11 | January 15, 2021 |
| 10.3† | First Amendment to the Amended and Restated Global Access Commitments Agreement, dated as of February 3, 2021, between the Registrant and the Bill & Melinda Gates Foundation | F-1/A | 333-252166 | 10.12 | February 3, 2021 |
| 10.4 | Lease, dated as of March 28, 2017, between the Registrant and MEPC MILTON PARK NO. 1 LIMITED and MEPC MILTON PARK NO. 2 LIMITED, on behalf of MEPC Milton LP | F-1 | 333-252166 | 10.13 | January 15, 2021 |
| 10.5 | Lease, dated as of December 28, 2017, between the Registrant and MEPC MILTON PARK NO. 1 LIMITED and MEPC MILTON PARK NO. 2 LIMITED, on behalf of MEPC Milton LP | F-1 | 333-252166 | 10.14 | January 15, 2021 |
| 10.6 | Lease, dated as of March 28, 2017, between the Registrant and MEPC MILTON PARK NO. 1 LIMITED and MEPC MILTON PARK NO. 2 LIMITED, on behalf of MEPC Milton LP | F-1 | 333-252166 | 10.15 | January 15, 2021 |
| 10.8# | Employment Agreement between the Registrant and Bahija Jallal, Ph.D., dated January 29, 2021 | F-1 | 333-252166 | 10.18 | January 15, 2021 |
| 10.9# | Employment Agreement between the Registrant and Travis Coy, dated December 31, 2024 | 10-K | 001-39992 | 10.9 | February 26, 2025 |
| 10.10# | Employment Agreement between the Registrant and David Berman, MD., Ph.D., dated January 29, 2021 | 10-K | 001-39992 | 10.13 | February 28, 2024 |
| 10.11# | Employment Agreement between the Registrant and Tina St Leger, dated August 2, 2021 | 10-K | 001-39992 | 10.14 | February 28, 2024 |
| 10.12 | Form of Deed of Indemnity between the Registrant and each of its directors | F-1 | 333-252166 | 10.1 | January 15, 2021 |
| 10.13 | Form of Deed of Indemnity between the Registrant and each of its executive officers | F-1 | 333-252166 | 10.2 | January 15, 2021 |
| 10.14 | Immunocore Holdings plc 2021 Equity Incentive Plan. and Non-Employee Sub Plan to the Immunocore Holdings plc 2021 Equity Incentive Plan | 20-F | 001-39992 | 4.20 | March 25, 2021 |
| 10.15 | Sales Agreement, dated as of September 9, 2022, by and between the Company and Jefferies LLC | 6-K | 001-39992 | 1.1 | September 9, 2022 |
| 10.16 | Registration Rights Agreement, dated May 28, 2024, by and among the Company and 667, L.P. and Baker Brothers Life Sciences, L.P. | 8-K | 001-39992 | 10.2 | May 28, 2024 |
| 10.17# | Form of Restricted Share Unit Agreement under 2021 Equity Incentive Plan | 10-K | 001-39992 | 10.17 | February 26, 2025 |
| 19.1 | Amended and Restated Insider Trading and Window Period Policy | 10-K | 001-39992 | 19.1 | February 26, 2025 |
| 21.1* | Subsidiaries of the Registrant | ||||
| 23.1* | Consent of Deloitte LLP | ||||
| 24.1* | Power of Attorney (incorporated by reference to the signature pages of this Annual Report on Form 10-K). | ||||
| 31.1* | Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||
| 31.2* | Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||
| 32.1** | Certification by the Principal Executive Officer and the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ||||
| 97.1 | Immunocore Holdings plc Incentive Compensation Recoupment Policy | 10-K | 001-39992 | 97.1 | February 28, 2024 |
| 101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
*Filed herewith.
**This certification is deemed furnished, not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.
†Certain portions of this exhibit (indicated by asterisks) have been redacted in accordance with Regulation S-K, Item 601(b)(10).
#Indicates a management contract or any compensatory plan, contract or arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.